Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 1, 2017

DrugPatentWatch Database Preview

Tapentadol hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for tapentadol hydrochloride and what is the scope of tapentadol hydrochloride patent protection?

Tapentadol hydrochloride
is the generic ingredient in two branded drugs marketed by Depomed Inc and is included in three NDAs. There are eight patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tapentadol hydrochloride has two hundred and fifty-five patent family members in thirty-six countries.

There are four drug master file entries for tapentadol hydrochloride. Seven suppliers are listed for this compound.

Summary for Generic Name: tapentadol hydrochloride

Tradenames:2
Patents:8
Applicants:1
NDAs:3
Drug Master File Entries: see list4
Suppliers / Packagers: see list7
Bulk Api Vendors: see list24
Clinical Trials: see list1,001
Patent Applications: see list218
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:tapentadol hydrochloride at DailyMed

Pharmacology for Ingredient: tapentadol hydrochloride

Drug ClassOpioid Agonist
Mechanism of ActionOpioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-004Aug 25, 2011RXYesNo8,420,056► SubscribeY ► Subscribe
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-001Nov 20, 2008RXYesNoRE39593► SubscribeYY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-005Aug 25, 2011RXYesYesRE39593► SubscribeYY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-005Aug 25, 2011RXYesYes8,114,383► SubscribeYY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-002Aug 25, 2011RXYesNo8,536,130► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Identify first generic entrants
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot